Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
Open Access
- 9 January 2009
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (1), 209-224
- https://doi.org/10.3390/ijerph6010209
Abstract
One hundred million deaths were caused by tobacco in the 20th century, and it is estimated that there will be up to one billion deaths attributed to tobacco use in the 21st century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global public health crisis with smoking being recognized as its most important causative factor. The most effective available treatment for COPD is smoking cessation. There is mounting evidence that the rate of progression of COPD can be reduced when patients at risk of developing the disease stop smoking, while lifelong smokers have a 50% probability of developing COPD during their lifetime. More significantly, there is also evidence that the risk of developing COPD falls by about half with smoking cessation. Several pharmacological interventions now exist to aid smokers in cessation; these include nicotine replacement therapy, bupropion, and varenicline. All pharmacotherapies for smoking cessation are more efficacious than placebo, with odds ratios of about 2. Pharmacologic therapy should be combined with nonpharmacologic (behavioral) therapy. Unfortunately, despite the documented efficacy of these agents, the absolute number of patients who are abstinent from smoking at 12 months of follow-up is low.Keywords
This publication has 94 references indexed in Scilit:
- Nanostructured and Spiky Gold Shell Growth on Magnetic Particles for SERS ApplicationsNanomaterials, 2020
- An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international expertsTobacco Control, 2009
- The of COPD: or balancing repair (yang) and inflammation (yin)European Respiratory Journal, 2008
- Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trialsCMAJ : Canadian Medical Association Journal, 2008
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- State of the Art. Chronic Obstructive Pulmonary Disease, Inflammation, and Lung CancerProceedings of the American Thoracic Society, 2006
- The neurobiological basis for partial agonist treatment of nicotine dependence: vareniclineInternational Journal of Clinical Practice, 2006
- Developments in pharmacotherapy for tobacco dependence: past, present and futureDrug and Alcohol Review, 2006
- Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokersEuropean Respiratory Journal, 2005
- Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatientsThorax, 2003